Overview of phosphodiesterase 5 inhibition in erectile dysfunction

American Journal of Cardiology

Volumn 92, Issue 9 SUPPL. 1, 2003, Pages 9-18

  Rosen, Raymond C ^a   Kostis, John B ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; CYCLIC GMP; NITRIC OXIDE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG; VARDENAFIL;

BACKACHE; CLINICAL TRIAL; COLOR VISION DEFECT; CONFERENCE PAPER; CORPUS CAVERNOSUM; DEGRADATION; DIABETES MELLITUS; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SCREENING; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG TOLERABILITY; DYSPEPSIA; ENZYME ANALYSIS; ENZYME INHIBITION; ERECTILE DYSFUNCTION; FLUSHING; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; INHIBITION KINETICS; ISCHEMIC HEART DISEASE; MEDICAL RESEARCH; MYALGIA; NAUSEA; NEUROCHEMISTRY; NOSE CONGESTION; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PENIS ERECTION; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RHINITIS; SEXUAL FUNCTION; SEXUAL INTERCOURSE; SIDE EFFECT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE RELAXATION; TREATMENT OUTCOME; VERTIGO; VISUAL DISORDER;

EID: 0242579616     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00824-5     Document Type: Conference Paper

References (37)

1. Boolell M., Allen M.J., Ballard S.A., Gepi-Attee S., Muirhead G.J., Naylor A.M., Osterloh I.H. Sildenafil an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile ED . Int J Impot Res. 8:1996;47-52.
2. Corbin J.D., Francis S.H. Cyclic GMP phosphodiesterase-5 target of sildenafil . J Biol Chem. 274:1999;13729-13732.
3. Lue T.F., Tanagho E.A. Physiology of erection and pharmacological management of impotence. J Urol. 137:1987;829-836.
4. Francis S.H., Turko I.V., Corbin J.D. Cyclic nucleotide phosphodiesterases relating structure and function . Prog Nucleic Acid Res Mol Biol. 65:2001;1-52.
5. Wallis R.M., Corbin J.D., Francis S.H., Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol. 83:(suppl):1999;3C-12C.
6. Moreland R.B., Hsieh G., Nakane M., Brioni J.D. The biochemical and neurologic basis for the treatment of male ED. J Pharmacol Exp Ther. 296:2001;225-234.
7. Gibson A. Phosphodiesterase 5 inhibitors and nitrergic transmission from zaprinast to sildenafil . Eur J Pharmacol. 411:2001;1-10.
8. Ückert S., Küthe A., Stief C.G., Jonas U. Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male ED. World J Urol. 19:2001;14-22.
9. Goldstein I., Lue T.F., Padma-Nathan H., Rosen R.C., Steers W.D., Wicker P.A. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 338:1998;1397-1404.
10. Padma-Nathan H. A new era in the treatment of erectile dysfunction. Am J Cardiol. 84:(suppl):1999;18N-23N.
11. Viagra® (sildenafil citrate) US prescribing information. In: Physicians' Desk Reference. 57th ed. Montvale, NJ: Medical Economics, 2003:2653-2656.
12. Zusman R.M., Morales A., Glasser D.B., Osterloh I.H. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol. 83:(suppl):1999;35C- 44C.
13. Sáenz de Tejada I., Angulo J., Cuevas P., Fernández A., Moncada I., Allona A., Lledó E., Körschen H.G., Niewöhner U., Haning H., Pages E., Bischoff E. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res. 13:2001;282-290.
14. Klotz T., Sachse R., Heidrich A., Jockenhövel F., Rohde G., Wensing G., Horstmann R., Engelmann R. Vardenafil increases penile rigidity and tumescence in ED patients a RigiScan and pharmacokinetic study . World J Urol. 19:2001;32-39.
15. Summary of Product Characteristics. Levitra European Public Assessment Report (EPAR). First published March 19, 2003 at: http://www. emea.eudra.org/humandocs/Humans/EPAR/levitra/levitraM.htm. Accessed July 28, 2003.
16. Angulo J., Gadau M., Fernandez A., Gabancho S., Cuevas P., Martins T., Florio V., Ferguson K., Sáenz de Tejada I. IC351 enhances NO-mediated relaxation of human arterial and trabecular penile smooth muscle. Eur Urol. 39:(suppl 5):2001;106. Abstract 415.
17. Patterson B., Bedding A., Jewell H., Payne C., Mitchell M. Dose-normalized pharmacokinetics of single-dose tadalafil (IC351) in healthy volunteers. Int J Impot Res. 13:(suppl 5):2001;S62. Abstract 14.
18. Patterson B., Bedding A., Jewell H., Payne C., Mitchell M. The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (IC351). Int J Impot Res. 13:(suppl 5):2001;S63. Abstract 16.
19. Summary of Product Characteristics. Cialis European Public Assessment Report (EPAR). First published June 12, 2002 at: http://www.emea.eudra.org/ humandocs/Humans/EPAR/cialis/cialisM.htm. Accessed July 28, 2003.
20. Rosen R.C., Riley A., Wagner G., Osterloh I.H., Kirkpatrick J., Mishra A. The International Index of Erectile Function (IIEF) a multidimensional scale for assessment of erectile dysfunction . Urology. 49:1997;822-830.
21. Jarow J.P., Burnett A.L., Geringer A.M. Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J Urol. 162:1999;722-725.
22. Conti C.R., Pepine C.J., Sweeney M. Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. Am J Cardiol. 83:(suppl):1999;29C-34C.
23. Sadovsky R., Miller T., Moskowitz M., Hackett G. Three-year update of sildenafil citrate (Viagra®) efficacy and safety. Int J Clin Pract. 55:2001;115-128.
24. Brindis RG, Kloner RA. Sildenafil in patients with cardiovascular disease. Am J Cardiol 2003;92(suppl 9A):26M-36M.
25. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil. Am J Cardiol 2003;92(suppl 9A):37M-46M.
26. Kloner RA, Mitchel M, Emmick JT. Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol 2003;92(suppl 9A):47M-57M.
27. Padma-Nathan H., McMurray J.G., Pullman W.E., Whitaker J.S., Saoud J.B., Ferguson K.M., Rosen R.C. On-demand IC351 (Cialis™) enhances erectile function in patients with erectile dysfunction. Int J Impot Res. 13:2001;2-9.
28. Sáenz de Tejada I., Anglin G., Knight J.R., Emmick J.T. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care. 25:2002;2159-2164.
29. Padma-Nathan H., Rosen R.C., Shabsigh R., Saikali K., Watkins V., Pullman W. Tadalafil (IC351) provides prompt response and extended period of responsiveness for the treatment of men with erectile dysfunction. Int J Impot Res. 13:(suppl 4):2001;S33. Abstract 88.
30. Porst H., Rosen R., Padma-Nathan H., Goldstein I., Giuliano F., Ulbrich E., Bandel T. The efficacy and tolerability of vardenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction the first at-home clinical trial . Int J Impot Res. 13:2001;192-199.
31. Steidle C, Feldman R, Lettieri J, Agarwal V, Segerson T. Pharmacokinetics of vardenafil (a new selective PDE5 inhibitor) in the elderly and subgroup data on efficacy and safety in elderly patients with erectile dysfunction. Paper presented at: Annual American Geriatrics Society Meeting; May 9-13, 2001; Chicago, Illinois.
32. Goldstein I., Young J.M., Fischer J., Bangerter K., Segerson T., Taylor T. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care. 26:2003;777-783.
33. Morales A., Gingell C., Collins M., Wicker P.A., Osterloh T.H. Clinical safety of oral sildenafil (Viagra™) in the treatment of erectile dysfunction. Int J Impot Res. 10:1998;69-74.
34. Yu G., Mason H.J., Wu X., Wang J., Chong S., Dorough G., Henwood A., Pongrac R., Seliger L., He B., et al. Substituted pyrazolopyridines as potent and selective PDE5 inhibitors potential targets for treatment of ED . J Med Chem. 44:2001;1025-1027.
35. DeBusk R., Drory Y., Goldstein I., Jackson G., Kaul S., Kimmel S.E., Kostis J.B., Kloner R.A., Lakin M., Meston C.M. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel. Am J Cardiol. 86:2000;175-181.
36. Data on file. Lilly ICOS LLC Bothell, WA, and Indianapolis, IN, 2003.
37. Rosen R.C. Sexual pharmacology in the 21st century. J Gend Specif Med. 3:2000;45-52.